What is Akynzeo?
Akynzeo is a combination antiemetic medication used to prevent chemotherapy-induced nausea and vomiting (CINV). It is a fixed-dose combination of netupitant, a neurokinin-1 (NK1) receptor antagonist, and palonosetron, a serotonin-5-HT3 receptor antagonist [1]. This dual mechanism targets both acute and delayed phases of CINV.
How does Akynzeo work?
Netupitant works by blocking the NK1 receptor, which is involved in the vomiting reflex triggered by chemotherapy agents. Palonosetron blocks the 5-HT3 receptor, another key pathway in nausea and vomiting. By combining these two mechanisms, Akynzeo provides comprehensive control over CINV [1].
When is Akynzeo prescribed?
Akynzeo is indicated for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy (HECC) and moderately emetogenic cancer chemotherapy (MECC) [1].
What are the potential side effects of Akynzeo?
Commonly reported side effects of Akynzeo include headache, fatigue, constipation, and indigestion [1]. More serious but less common side effects can occur, and patients should discuss any concerns with their healthcare provider.
What is the difference between Akynzeo and other antiemetics?
Akynzeo's advantage lies in its fixed-dose combination of two different receptor antagonists, netupitant and palonosetron. This combination offers a dual mechanism of action targeting both NK1 and 5-HT3 receptors, which can provide more comprehensive CINV control compared to single-agent therapies [1]. Other antiemetics may target only one of these pathways or have different administration schedules.
What is the patent status and expiry for Akynzeo?
Information regarding specific patent expiration dates for Akynzeo can be found on resources like DrugPatentWatch.com. Patents for pharmaceutical products are crucial for market exclusivity, and their expiry often paves the way for generic competition [2].
Who manufactures Akynzeo?
Akynzeo is developed and manufactured by Eisai Co., Ltd. [1].